Continued ocrelizumab treatment for people with multiple sclerosis from earlier studies
Tests continued ocrelizumab and physical effects of multiple sclerosis in adults previously in a study.
Plain-language title generated from the registry record
Registry title: An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Key facts
- Where
- Pleven, Sofia, and Sofiya, BulgariaSee the 5 sites
- Phase
- Phase 3
Where in Bulgaria
- Multiprofile Hospital For Active Treatment Avis Medika OODPleven, BulgariaTaking people
- University Multiprofile Hospital for Active Treatment Dr Georgi Stranski EADPleven, BulgariaTaking people
- Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EADSofia, BulgariaTaking people
- Military Medical AcademySofiya, BulgariaTaking people
- University First multiprofile hospital for active treatment Sofia St. Joan Krastitel EADSofiya, BulgariaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT06675955EU 2023-507633-21-01
- Record updated
- 28 October 2026
- Original description
The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.Read full original descriptionShow less
An Open-label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients With Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and Without Access to a Post-trial Access Program
The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.
From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.
Inclusion: Participants who were on ongoing ocrelizumab treatment on one of the following parent-studies [Studies MN39159/CONSONANCE (NCT03523858), BN42082/MUSETTE (NCT04544436), BN42083/GAVOTTE (NCT04548999), BN44083/GLOBEAM, MN43978/CONSONANCE Ext., WA40404/O'HAND (NCT04035005), MN43964/OLERO (NCT05269004), GN41791/FENTREPID (NCT04544449), BP46016/MINTAKA, CN41144/OCARINA I-SC (NCT03972306), CN42097/OCARINA II-SC (NCT05232825)] at the time of roll-over and who do not have access to the ocrelizumab treatment locally; The first dose of study treatment in this extension study will be received no earlier than 5 months after the last treatment in the parent study; Negative urine pregnancy test within 24 hours to first dose administered on MN45053 study treatment in participants of childbearing potential.
Exclusion: Concurrent participation in any therapeutic clinical trial (other than the parent study); Study treatment is commercially marketed in the participant's country for the participant-specific disease and is reasonably accessible to the participant; Any condition that, in the opinion of the investigator, would interfere with the interpretation of participant safety or place the participant at high risk for treatment-related complications; Known active malignancy or are being actively monitored for recurrence of malignancy; Known presence of other neurological disorders; Study treatment is available via Post Trial Access Program (PTAP) in the participant's country and is accessible to the participant; Permanent premature discontinuation of study treatment for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable); Immunocompromised state.